Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding BioTime is 'Not Rated'. Macroaxis provides BioTime buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BioTime positions. The advice algorithm takes into account all of BioTime available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BioTime buy-and-hold prospective. Check also Trending Equities.
For the selected time horizon BioTime has a risk adjusted performance of 0.0576, jensen alpha of 0.4407, total risk alpha of (0.18), sortino ratio of 0.0746 and treynor ratio of 0.4922Macroaxis provides buy, hold, or sell suggestion on BioTime to complement and cross-verify current analyst consensus on BioTime. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure BioTime is not overpriced, please confirm all BioTime fundamentals including its Cash and Equivalents, and the relationship between Revenue and Current Ratio .
BioTime Returns Distribution Density
|Mean Return||0.52||Value At Risk||7.94|
|Potential Upside||16.89||Standard Deviation||7.61|
|BioTime is not yet fully synchronised with the market data|
|BioTime appears to be very risky and stock price may revert if volatility continues|
|The company reported revenue of 5.23M. Net Loss for the year was (72.97M) with profit before overhead, payroll, taxes, and interest of 3.29M.|
|BIOTIME has accumulated about 21.44M in cash with (30.75M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.|
|Roughly 46.0% of the company shares are held by company insiders|